IMMUNEERING CORP - CLASS A
IMRXNASDAQTrading Snapshot
- Day Range
- $4.86 – $4.97
- 52-Week Range
- $2.90 – $10.08
- Volume
- $2.81B
- Avg Volume
- $2.11B
- Shares Outstanding
- 64.7M
- Next Earnings
- Sep 30, 2026
Fundamentals Snapshot
- Annual Revenue
- $529,803
- Last Q Revenue
- $138,194
- P/E Ratio
- —
- P/S Ratio
- 586.2x
- EPS (TTM)
- $-1.03
- Dividend Yield
- —
Why Investors Own IMRX
- ✓High-growth profile — revenue up +18.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 37% gross margin and 11% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About IMMUNEERING CORP - CLASS A
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors. Beyond these advanced-stage programs, Immuneering's early-stage pipeline includes five oncology initiatives aimed at components of the MAPK or mTOR signaling pathways, along with two neuroscience programs, all currently in the discovery phase. Founded in 2008, Immuneering Corporation is headquartered in Cambridge, Massachusetts. It was formerly a subsidiary of Teva Pharmaceutical Industries Limited.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
Wall Street analysts change outlook on top names. Check analyst ratings page for all changes. See what analysts say about LYEL, IMRX, and RNA.
HC Wainwright & Co. Initiates Coverage On Immuneering with Buy Rating, Announces Price Target of $14
HC Wainwright & Co. analyst Andres Y. Maldonado initiates coverage on Immuneering (NASDAQ:IMRX) with a Buy rating and announces Price Target of $14.
Immuneering Q2 EPS $(0.27), Inline
Immuneering (NASDAQ:IMRX) reported quarterly losses of $(0.27) per share which met the analyst consensus estimate. This is a 32.5 percent increase over losses of $(0.40) per share from the same period last year.
Immuneering: A Third (Much Cheaper) Way To Invest In The RAS-RAF-MEK-ERK 'Revolution'
Immuneering update: atebimetinib shows strong Phase 2a survival in 1L pancreatic cancer; Phase 3 recruiting. Click for more on IMRX stock.
Immuneering Publishes New Findings In Cancer Research Characterizing The Differentiated Mechanism And Broad Preclinical Activity Of Atebimetinib; Atebimetinib Showed Broad Antitumor Activity Across KRAS-, NRAS-, And BRAF-mutant Models, Including Colorectal, Lung, And Melanoma, By Resisting The RAF-Mediated Bypass Signaling That Has Constrained Other MEK Inhibitors
- Atebimetinib showed broad antitumor activity across KRAS-, NRAS-, and BRAF-mutant models, including colorectal, lung, and melanoma, by resisting the RAF-mediated bypass signaling that has constrained other MEK
Needham Maintains Buy on Immuneering, Raises Price Target to $18
Needham analyst Ami Fadia maintains Immuneering (NASDAQ:IMRX) with a Buy and raises the price target from $11 to $18.